Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma

Experimental and Molecular Pathology

Volumn 93, Issue 1, 2012, Pages 147-153

  Trowbridge, Ryan ^a   Sharma, Poonam ^a   Hunter, William J ^a   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Esophageal cancer; Neoadjuvant therapy; Vitamin D; Vitamin D receptor

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL; VITAMIN D RECEPTOR;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CELL DEDIFFERENTIATION; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTORS, CALCITRIOL; RETROSPECTIVE STUDIES;

EID: 84860821724     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.04.018     Document Type: Article

References (34)

1. Barbour A.P., Jones M., Gonen M., Gotley D.C., Thomas J., Thomson D.B., et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Annals of Surgical Oncology 2008, 15(10):2894-2902.
2. Beno D.W., Brady L.M., Bissonnette M., Davis B.H. Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated Egr induction. The Journal of Biological Chemistry 1995, 270(8):3642-3647.
3. Blomberg Jensen M., Andersen C.B., Nielsen J.E., Bagi P., Jorgensen A., Juul A., et al. Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. The Journal of Steroid Biochemistry and Molecular Biology 2010, 121(1-2):376-382.
4. Bollschweiler E., Metzger R., Drebber U., Baldus S., Vallbohmer D., Kocher M., et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Annals of Oncology 2009, 20(2):231-238.
5. Brozyna A.A., Jozwicki W., Janjetovic Z., Slominski A.T. Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Human Pathology 2011, 42(5):618-631.
6. Chung I., Han G., Seshadri M., Gillard B.M., Yu W.D., Foster B.A., et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Research 2009, 69(3):967-975.
7. Courrech Staal E.F., Aleman B.M., Boot H., van Velthuysen M.L., van Tinteren H., van Sandick J.W. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. The British Journal of Surgery 2010, 97(10):1482-1496.
8. Crehange G., Bonnetain F., Peignaux K., Truc G., Blanchard N., Rat P., et al. Preoperative radiochemotherapy for resectable localised oesophageal cancer: a controversial strategy. Critical Reviews in Oncology/Hematology 2010, 75(3):235-242.
9. De Gottardi A., Dumonceau J.M., Bruttin F., Vonlaufen A., Morard I., Spahr L., et al. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Molecular Cancer 2006, 5:48.
10. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews. Cancer 2007, 7(9):684-700.
11. Donahue J.M., Nichols F.C., Li Z., Schomas D.A., Allen M.S., Cassivi S.D., et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. The Annals of Thoracic Surgery 2009, 87(2):392-398. (discussion 8-9).
12. Eelen G., Gysemans C., Verlinden L., Vanoirbeek E., De Clercq P., Van Haver D., et al. Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs. Current Medicinal Chemistry 2007, 14(17):1893-1910.
13. Gertler R., Stein H.J., Langer R., Nettelmann M., Schuster T., Hoefler H., et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Annals of Surgery 2011, 253(4):689-698.
14. Hendrickson W.K., Flavin R., Kasperzyk J.L., Fiorentino M., Fang F., Lis R., et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. Journal of Clinical Oncology 2011, 29(17):2378-2385.
15. Hulscher J.B., van Sandick J.W., de Boer A.G., Wijnhoven B.P., Tijssen J.G., Fockens P., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. The New England Journal of Medicine 2002, 347(21):1662-1669.
16. Kure S., Nosho K., Baba Y., Irahara N., Shima K., Ng K., et al. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention 2009, 18(10):2765-2772.
17. Kwon H.C., Roh M.S., Oh S.Y., Kim S.H., Kim M.C., Kim J.S., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Annals of Oncology 2007, 18(3):504-509.
18. Mahmoudi T., Arkani M., Karimi K., Safaei A., Rostami F., Arbabi E., et al. The -4817 G>A (rs2238136) variant of the vitamin D receptor gene: a probable risk factor for colorectal cancer. Molecular Biology Reports 2012, 39(5):5277-5282.
19. Mangelsdorf D. VDR: Anatomical Q-PCR Expression Data 2005, Nuclear Receptor Signaling Atlas.
20. Matusiak D., Murillo G., Carroll R.E., Mehta R.G., Benya R.V. Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiology, Biomarkers & Prevention 2005, 14(10):2370-2376.
21. McKenzie S., Mailey B., Artinyan A., Metchikian M., Shibata S., Kernstine K., et al. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy. Annals of Surgical Oncology 2011, 18(2):551-558.
22. Meggouh F., Lointier P., Pezet D., Saez S. Evidence of 1,25-dihydroxyvitamin D3-receptors in human digestive mucosa and carcinoma tissue biopsies taken at different levels of the digestive tract, in 152 patients. Journal of Steroid Biochemistry 1990, 36(1-2):143-147.
23. Meredith K.L., Weber J.M., Turaga K.K., Siegel E.M., McLoughlin J., Hoffe S., et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Annals of Surgical Oncology 2010, 17(4):1159-1167.
24. Merkow R.P., Bilimoria K.Y., McCarter M.D., Chow W.B., Gordon H.S., Stewart A.K., et al. Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. Cancer 2011, Oct 17. doi: 10.1002/cncr.26608. [Electronic publication ahead of print].
25. Metzger R., Warnecke-Eberz U., Alakus H., Kutting F., Brabender J., Vallbohmer D., et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. Journal of Gastrointestinal Surgery 2012, 16(1):26-34. discussion 34.
26. Milde P., Hauser U., Simon T., Mall G., Ernst V., Haussler M.R., et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. The Journal of Investigative Dermatology 1991, 97(2):230-239.
27. Mimori K., Tanaka Y., Yoshinaga K., Masuda T., Yamashita K., Okamoto M., et al. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Annals of Oncology 2004, 15(2):236-241.
28. Muti P., Benassi B., Falvo E., Santoro R., Galanti S., Citro G., et al. Omics underpins novel clues on VDR chemoprevention target in breast cancer. OMICS 2011, 15(6):337-346.
29. Reichrath J., Kamradt J., Zhu X.H., Kong X.F., Tilgen W., Holick M.F. Analysis of 1,25-dihydroxyvitamin D(3) receptors (VDR) in basal cell carcinomas. The American Journal of Pathology 1999, 155(2):583-589.
30. Ruol A., Castoro C., Portale G., Cavallin F., Sileni V.C., Cagol M., et al. Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. Archives of Surgery 2009, 144(3):247-254. (discussion 54).
31. Schmidt D.R., Mangelsdorf D.J. Nuclear receptors of the enteric tract: guarding the frontier. Nutrition Reviews 2008, 66(10 Suppl. 2):S88-S97.
32. Schneider P.M., Baldus S.E., Metzger R., Kocher M., Bongartz R., Bollschweiler E., et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Annals of Surgery 2005, 242(5):684-692.
33. Schwer A.L., Ballonoff A., McCammon R., Rusthoven K., D'Agostino R.B., Schefter T.E. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. International Journal of Radiation Oncology, Biology, Physics 2009, 73(2):449-455.
34. Welsh J. Cellular and molecular effects of vitamin D on carcinogenesis. Archives of Biochemistry and Biophysics 2011, Nov 9. [Electronic publication ahead of print].